

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

SCHEDULE 13D

Under the Securities Exchange Act of 1934  
(Amendment No. )\*

CYTOCLONAL PHARMACEUTICS

---

(Name of Issuer)

Common Stock

---

(Title of Class of Securities)

23282G105

---

(CUSIP Number)

Paul F. Byrne c/o Janssen-Meyers Associates, L.P. 17 State Street, NY, NY  
10004  
(212) 742-4200

---

(Name, Address and Telephone Number of Person Authorized to  
Receive Notices and  
Communications)

11/2/95

---

(Date of Event which Requires Filing of this Statement)

If the filing person has previously filed a statement on  
Schedule 13G to report the acquisition which is the  
subject of this Schedule 13D, and is filing this schedule because  
of Rule 13d-1(b)(3) or (4), check the  
following box \_\_\_\_.

Check the following box if a fee is being paid with the  
statement \_\_\_\_\_. (A fee is not required only if the  
reporting person: (1) has a previous statement on file  
reporting beneficial ownership of more than five  
percent of the class of securities described in Item 1; and  
(2) has filed no amendment subsequent thereto  
reporting beneficial ownership of five percent or less of  
such class.) (Sec Rule 13d-7.)

Note: Six copies of this statement, including all  
exhibits, should be  
filed with the Commission. See Rule  
13d-1(a) for other parties to whom copies are to be sent.

\*The remainder of this cover page shall be filled out for a  
reporting person's initial filing on this form with  
respect to the subject class of securities, and for any  
subsequent amendment containing information which  
would alter disclosures provided in a prior cover page.

The information required on the remainder of this cover  
page shall not be deemed to be "filed" for the  
purpose of Section 18 of the Securities Exchange Act of  
1934 ("Act") or otherwise subject to the liabilities  
of that section of the Act but shall be subject to all  
other provisions of the Act (however, see the Notes).

1. Name of Reporting Person  
Bruce Meyers

---

S.S. or I.R.S. Identification No. of Above Person

SS # ###-##-####

---

2. Check the Appropriate Box if a Member of a Group  
(See Instructions before filling out)

a. \_\_\_\_\_ b. ☒ X \_\_\_\_\_

3. SEC USE ONLY

---

4. Source of Funds (See instructions before filling out).

AF

---

5. Check Box if Disclosure of Legal Proceedings is  
Required Pursuant to Items  
2(d) or 2(e).

---

6. Citizenship or Place of Organization

USA

---

NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON  
(Questions 7 - 10)

7. Sole Voting Power

---

8. Shared Voting Power

849,500 Common Stock

---

9. Sole Dispositive Power

---

10. Shared Dispositive Power

849,500 shares Common Stock

---

11. Aggregate Amount Beneficially Owned by Each Reporting Person

849,500 shares Common Stock

---

12. Check Box if the Aggregate Amount in Row (11) Excludes Certain Shares  
(See instructions before filling out)

NA

---

13. Percent of Class Represented by Amount in Row (11)

11.6%

---

14. Type of Reporting Person (See instructions before filling out)

